Celcuity drug Revtorpyk is now approved for advanced cases of the most common type of breast cancer that do not harbor a certain mutation. The intravenously infused medicine is first in a new drug class that addresses a pathway associated with many cancers.
The post Celcuity’s First-in-Class Drug Gets FDA Approval in Most Common Type of Breast Cancer appeared first on MedCity News.
